Aberdeen Group Reduces Align Technology Holdings

Institutional investor trims stake in medical equipment provider

Apr. 9, 2026 at 7:22am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of the intricate inner workings of a dental scanner, conveying the sophisticated engineering and manufacturing behind Align Technology's medical equipment.An institutional investor's reduced stake in Align Technology highlights the complex financial landscape surrounding the medical device company's advanced dental technology.Tempe Today

Aberdeen Group plc, an institutional investor, lowered its position in Align Technology, Inc. (NASDAQ:ALGN) by 12.3% during the fourth quarter, according to a recent SEC filing. The firm owned 47,732 shares of the medical equipment provider's stock after selling 6,717 shares.

Why it matters

Align Technology is a leading provider of clear aligners and intraoral scanners for the dental industry. Changes in institutional ownership can signal shifts in market sentiment and investor confidence around the company's performance and future prospects.

The details

According to the 13F filing, Aberdeen Group plc reduced its stake in Align Technology from 54,449 shares to 47,732 shares during the fourth quarter. The firm's holdings were valued at $7,453,000 at the end of the quarter.

  • Aberdeen Group plc filed the 13F disclosure for the fourth quarter of 2025 on April 9, 2026.

The players

Aberdeen Group plc

A global investment management firm that provides a range of investment products and services to institutional and individual clients worldwide.

Align Technology, Inc.

A medical device company that designs, manufactures, and markets the Invisalign system, a series of clear removable aligners used in orthodontic treatment, as well as intraoral scanners and CAD/CAM software for dental professionals.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Aberdeen Group's Align Technology holdings suggests a potential shift in investor sentiment around the company's prospects, though the overall rationale behind the move is unclear. Investors will likely monitor Align's financial performance and market positioning in the coming quarters to gauge the broader investment landscape for the medical equipment provider.